PRX
PRX is a protein involved in peripheral nerve myelin upkeep. The encoded protein contains 2 PDZ domains which were named after PSD95 (post synaptic density protein), DlgA (Drosophila disc large tumor suppressor), and ZO1 (a mammalian tight junction protein). Two alternatively spliced transcript variants have been described for this gene which encode different protein isoforms and which are targeted differently in the Schwann cell.
Full Name
Periaxin
Function
Scaffolding protein that functions as part of a dystroglycan complex in Schwann cells, and as part of EZR and AHNAK-containing complexes in eye lens fiber cells. Required for the maintenance of the peripheral myelin sheath that is essential for normal transmission of nerve impulses and normal perception of sensory stimuli. Required for normal transport of MBP mRNA from the perinuclear to the paranodal regions. Required for normal remyelination after nerve injury. Required for normal elongation of Schwann cells and normal length of the internodes between the nodes of Ranvier. The demyelinated nodes of Ranvier permit saltatory transmission of nerve impulses; shorter internodes cause slower transmission of nerve impulses. Required for the formation of appositions between the abaxonal surface of the myelin sheath and the Schwann cell plasma membrane; the Schwann cell cytoplasm is restricted to regions between these appositions. Required for the formation of Cajal bands and of Schmidt-Lanterman incisures that correspond to short, cytoplasm-filled regions on myelinated nerves. Recruits DRP2 to the Schwann cell plasma membrane. Required for normal protein composition of the eye lens fiber cell plasma membrane and normal eye lens fiber cell morphology.
Biological Process
Axon ensheathment1 PublicationNAS:UniProtKB
Peripheral nervous system myelin maintenanceManual Assertion Based On ExperimentIBA:GO_Central
Regulation of RNA splicingManual Assertion Based On ExperimentIBA:GO_Central
Peripheral nervous system myelin maintenanceManual Assertion Based On ExperimentIBA:GO_Central
Regulation of RNA splicingManual Assertion Based On ExperimentIBA:GO_Central
Involvement in disease
Dejerine-Sottas syndrome (DSS):
A severe degenerating neuropathy of the demyelinating Charcot-Marie-Tooth disease category, with onset by age 2 years. Characterized by motor and sensory neuropathy with very slow nerve conduction velocities, increased cerebrospinal fluid protein concentrations, hypertrophic nerve changes, delayed age of walking as well as areflexia. There are both autosomal dominant and autosomal recessive forms of Dejerine-Sottas syndrome.
Charcot-Marie-Tooth disease 4F (CMT4F):
A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4. CMT4F is characterized by distal sensory impairment and distal muscle weakness and atrophy affecting the lower more than the upper limbs. The age at onset is variable and can range from childhood to adult years. When the onset is in infancy, the phenotype is characterized as Dejerine-Sottas syndrome.
A severe degenerating neuropathy of the demyelinating Charcot-Marie-Tooth disease category, with onset by age 2 years. Characterized by motor and sensory neuropathy with very slow nerve conduction velocities, increased cerebrospinal fluid protein concentrations, hypertrophic nerve changes, delayed age of walking as well as areflexia. There are both autosomal dominant and autosomal recessive forms of Dejerine-Sottas syndrome.
Charcot-Marie-Tooth disease 4F (CMT4F):
A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4. CMT4F is characterized by distal sensory impairment and distal muscle weakness and atrophy affecting the lower more than the upper limbs. The age at onset is variable and can range from childhood to adult years. When the onset is in infancy, the phenotype is characterized as Dejerine-Sottas syndrome.
View more
Anti-PRX antibodies
+ Filters
Loading...
Target: PRX
Host: Mouse
Antibody Isotype: IgG
Specificity: Human, Mouse, Rat
Clone: G-5
Application*: WB, IP, IF, E
More Infomation
Hot products 
-
Mouse Anti-dsDNA Recombinant Antibody (22) (CBMAB-AP1954LY)
-
Mouse Anti-APP Recombinant Antibody (DE2B4) (CBMAB-1122-CN)
-
Mouse Anti-NSUN6 Recombinant Antibody (D-5) (CBMAB-N3674-WJ)
-
Rabbit Anti-AP2M1 (Phosphorylated T156) Recombinant Antibody (D4F3) (PTM-CBMAB-0610LY)
-
Mouse Anti-CD33 Recombinant Antibody (P67.6) (CBMAB-C10189-LY)
-
Mouse Anti-CD2AP Recombinant Antibody (BR083) (CBMAB-BR083LY)
-
Mouse Anti-CDK7 Recombinant Antibody (CBYY-C1783) (CBMAB-C3221-YY)
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0442) (CBMAB-0445-YY)
-
Mouse Anti-ACLY Recombinant Antibody (V2-179314) (CBMAB-A0610-YC)
-
Mouse Anti-BRD3 Recombinant Antibody (CBYY-0801) (CBMAB-0804-YY)
-
Mouse Anti-ALPL Antibody (B4-78) (CBMAB-1009CQ)
-
Mouse Anti-AMACR Recombinant Antibody (CB34A) (CBMAB-CA034LY)
-
Mouse Anti-CECR2 Recombinant Antibody (CBWJC-2465) (CBMAB-C3533WJ)
-
Mouse Anti-APCS Recombinant Antibody (CBYC-A663) (CBMAB-A3054-YC)
-
Mouse Anti-EIF4G1 Recombinant Antibody (2A9) (CBMAB-A2544-LY)
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0435) (CBMAB-0437-YY)
-
Mouse Anti-CD59 Recombinant Antibody (CBXC-2097) (CBMAB-C4421-CQ)
-
Mouse Anti-ARG1 Recombinant Antibody (CBYCL-103) (CBMAB-L0004-YC)
-
Mouse Anti-ALB Recombinant Antibody (V2-55272) (CBMAB-H0819-FY)
-
Mouse Anti-CCND2 Recombinant Antibody (DCS-3) (CBMAB-G1318-LY)
For Research Use Only. Not For Clinical Use.
(P): Predicted
* Abbreviations
- AActivation
- AGAgonist
- APApoptosis
- BBlocking
- BABioassay
- BIBioimaging
- CImmunohistochemistry-Frozen Sections
- CIChromatin Immunoprecipitation
- CTCytotoxicity
- CSCostimulation
- DDepletion
- DBDot Blot
- EELISA
- ECELISA(Cap)
- EDELISA(Det)
- ESELISpot
- EMElectron Microscopy
- FFlow Cytometry
- FNFunction Assay
- GSGel Supershift
- IInhibition
- IAEnzyme Immunoassay
- ICImmunocytochemistry
- IDImmunodiffusion
- IEImmunoelectrophoresis
- IFImmunofluorescence
- IGImmunochromatography
- IHImmunohistochemistry
- IMImmunomicroscopy
- IOImmunoassay
- IPImmunoprecipitation
- ISIntracellular Staining for Flow Cytometry
- LALuminex Assay
- LFLateral Flow Immunoassay
- MMicroarray
- MCMass Cytometry/CyTOF
- MDMeDIP
- MSElectrophoretic Mobility Shift Assay
- NNeutralization
- PImmunohistologyp-Paraffin Sections
- PAPeptide Array
- PEPeptide ELISA
- PLProximity Ligation Assay
- RRadioimmunoassay
- SStimulation
- SESandwich ELISA
- SHIn situ hybridization
- TCTissue Culture
- WBWestern Blot
Online Inquiry




